Popular

Retatrutide 5mg

5mg | Third-Party Tested | 99% Purity | COA Available | Research Use Only

Retatrutide, also known as LY3437943, is an investigational synthetic peptide.

$54.00

0 out of 5 · 0 ratings

Be the first to rate this compound:

2 in stock

Buy Retatrutide 5 mg| 99% Purity| COA Available

Retatrutide (LY3437943) is an investigational peptide studied by research. It is designed to act on three key receptors in the body: GLP-1, GIP, and glucagon. Because of this, researchers are studying it for weight management, type 2 diabetes, and other metabolic conditions such as NAFLD and MASH. The 5 mg presentation refers to the total peptide content in the vial. Like other versions, retatrutide is a long-acting compound with an approximate half-life of six days. In research settings, it is commonly administered through subcutaneous injection, which supports once-weekly dosing protocols. This peptide is provided as a lyophilized (freeze-dried) powder. Before use in research, it must be properly reconstituted under controlled conditions. As of 2026, retatrutide is still in phase 3 clinical trials under the TRIUMPH program. It has not been approved by the FDA, EMA, or MHRA. It is not available for medical use, compounding, or personal consumption. Retatrutide is strictly intended for laboratory research, including in vitro studies, animal testing, and approved clinical trials.

How Retatrutide Works in Research

Retatrutide functions as a triple receptor agonist with differentiated activity across GLP-1, GIP, and glucagon receptors. Binding affinity occurs at nanomolar levels.

Reported EC50 values include:

GIP receptor: Approximately 0.064 nM GLP-1 receptor: Approximately 0.775 nM Glucagon receptor: Approximately 5.79 nM In research models, retatrutide activates several metabolic pathways.

GLP-1 receptor activation reduces appetite through central signaling. It slows gastric emptying. It increases glucose-dependent insulin secretion. It also suppresses glucagon during hyperglycemia.
GIP receptor activation enhances insulin release. It supports beta-cell function. It influences fat storage and metabolism.
Glucagon receptor activation may increase energy expenditure and lipid metabolism, though its effects on glucose levels are carefully monitored in clinical trials.

This combined activity reduces food intake and improves insulin sensitivity. It also increases metabolic rate. Studies suggest a greater proportion of fat mass reduction compared to lean mass, though body composition outcomes may vary. This profile differs from single or dual agonists.

Retatrutide Peptide Structure and Properties

Retatrutide (LY3437943) is a synthetic peptide containing 39 amino acids. It is designed to interact with three receptors: GLP-1, GIP, and glucagon receptors. Its structure includes amino acid modifications and a fatty acid side chain that influence its stability and receptor activity.

Chemical Properties of Retatrutide

Property	Correct Information
Compound Name	Retatrutide
Research Code	LY3437943
Molecular Formula	C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight	Approximately 4,731 g/mol
CAS Number	2381089-83-2
PubChem CID	171390338 (Triple G structural record)
Amino Acid Length	39 residues
Peptide Type	Synthetic lipidated peptide
Receptor Targets	GLP-1R, GIPR, and GCGR
Physical Form	Lyophilized powder (supplier-dependent)
Research Status	Investigational compound

The molecular formula, molecular weight, and CAS number are supported by published chemical records.

Findings from Retatrutide Studies

Retatrutide shows strong results in metabolic research. Data come from preclinical studies and phase 2 trials.

1. Obesity Research About Retatrutide

A phase 2 randomized trial published in NEJM included 338 adults. Participants had obesity or overweight with comorbidities. Once-weekly retatrutide produced dose-dependent weight loss. At 48 weeks, the 12 mg dose achieved about 24 percent weight reduction. Placebo groups showed minimal change. Most participants reached significant milestones. Over 90 percent lost at least 10 percent body weight, and more than 80 percent lost at least 15 percent. Improvements were also noted in waist size, lipid levels, and blood pressure.

2. Type 2 Diabetes Research About Retatrutide

HbA1c reductions up to 2.02 percent were in phase 2 trials. Results exceeded those of the placebo and some comparator arms. Participants also experienced substantial weight loss.

3. Liver Fat and NAFLD Models

In participants with elevated liver fat, retatrutide reduced hepatic fat by over 80 percent. Most high-dose participants reached normal liver fat levels.

Additional Research Areas Where Retatrutide May Benefit

Phase 3 TRIUMPH trials study osteoarthritis, cardiovascular risk, kidney disease, and MASH. Some late-stage trial reports suggest weight reductions approaching 25–29% at higher doses over extended periods. Safety data show mostly mild gastrointestinal effects. These include nausea, diarrhea, and vomiting. Events are dose-related and often improve with titration. Serious hypoglycemia and major cardiac events remain rare in trials. Early data suggest greater efficacy than dual agonists. Retatrutide serves as a benchmark compound in triple-hormone research.

Retatrutide Peptide Prices at Orion Peptides

Retatrutide Compound	Price
Retatrutide 5 mg	$54
Retatrutide 10 mg	$81
Retatrutide 15 mg	$119
Retatrutide 20 mg	$145
Retatrutide 30 mg	$193

Disclaimer

Retatrutide is an investigational research compound. Currently, in 2026, it remains in phase 3 clinical trials. It is not approved for prescription or commercial use. Any non-trial compounds labeled as retatrutide may be counterfeit. Such compounds pose serious safety risks. Clinical and preclinical data do not guarantee future approval. No claims are made regarding safety or efficacy. Use is limited to qualified research settings. IRB or ethics approval is required for human studies. Regulatory restrictions may apply.

Referenced Citations

Research Use Only

This compound is intended for laboratory research use only. It is not intended for human or animal consumption, or for use in diagnostic or therapeutic procedures.

Chemical Properties

Property	Value
Molecular Formula	C221H342N46O68
Molecular Mass	4731 g/mol
Monoisotopic Mass	4728.4717592 Da
Polar Area	1780 Å²
Complexity	11,500
XLogP	-6.3
Heavy Atom Count	335
Hydrogen Bond Donors	58
Hydrogen Bond Acceptors	70
Rotatable Bonds	159
PubChem CID	171390338
InChIKey	MLOLQJNKXBNWFW-SAGGEDDASA-N
IUPAC Name	20-[[(1S)-4-[2-[2-[2-[[(5S)-5-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-2,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]-6-[[(2S)-1-[[(2S)-5-amino-1-[[1-[[(2S)-1-[[(2S)-1-[[(3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-[[(2S)-1-amino-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
SMILES	CC[C@H](C)C(C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](C)NC(=O)C(C)(C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@](C)(CC(C)C)NC(=O)C([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CC7=CC=C(C=C7)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C(C)(C)NC(=O)[C@H](CC9=CC=C(C=C9)O)N

Certificate of Analysis

Quality

Every batch of Retatrutide 5mg is tested for purity and identity using industry-standard methods.

HPLC Analysis

High-Performance Liquid Chromatography confirms purity ≥99%. Each batch is analyzed to ensure consistent quality.

Mass Spectrometry (MS)

Identity verification via mass spectrometry confirms correct molecular weight of 4113.58 g/mol.

Third-Party Testing

All compounds undergo independent third-party laboratory testing for quality assurance.

Request COA

Certificate of Analysis documents are available for all compounds. Contact us with your order number to request batch-specific documentation.

COA Lab Tests

Each compound batch is tested by independent laboratories to verify purity, identity, and quality. The Certificate of Analysis (COA) provides transparent lab results, ensuring the compound meets strict research-grade standards.

Storage & Handling

Before Use (Uno⁠pened)

Store i‍n refri‌gerator at 2⁠°C‍ to 8°C, equivalent to‍ 36°F t‍o 46‌°F tem⁠perature r‌ange
Keep temperature consisten⁠t at a⁠ll‌ times

Store i‍n the main refrigerator compartment, avoid storing in the refrigerat⁠or do⁠or

‍Keep in o⁠ri⁠ginal p⁠a⁠c‍k⁠ag‌ing⁠ always

A‌fter Reconst‌itution (Liquid Form)

Continu⁠e⁠ refrigerat⁠ing⁠ at 2°‍C to 8°C⁠, 36°F and 46°F consistently
Ke‍ep the liquid form refrigerate‍d between dose‍s
R‌eturn to refrigerator immediately after use

Storage During Travel‌

‍Keep‌ in original packaging
Minimize time outside p‍roper storage
Retu⁠rn t⁠o refrigerator promptly upon arrival
Plan ahead for ext‍ended trav‌el

A‌fter Reconst‌itution (Liquid Form)

Continu⁠e⁠ refrigerat⁠ing⁠ at 2°‍C to 8°C⁠, 36°F and 46°F consistently
Ke‍ep the liquid form refrigerate‍d between dose‍s
R‌eturn to refrigerator immediately after use

Add

Test	Method	Result	Specification
Identity	HPLC-DAD	Retatrutide	Retatrutide	Pass
Purity	HPLC-DAD	99.41	>99% by HPLC	Pass
Quantity	HPLC Analyte Concentration Curve Assay	5.15	5mg	Pass
Endotoxins	LAL ELISA	0.131 EU/mL	≤ 0.5 EU/mL	Pass
Sterility	Pour Plate	No Growth	No Growth	Pass

Retatrutide 5mg

Bulk Pricing – Save More

Buy Retatrutide 5 mg| 99% Purity| COA Available

How Retatrutide Works in Research

Reported EC50 values include:

Retatrutide Peptide Structure and Properties

Chemical Properties of Retatrutide

Findings from Retatrutide Studies

1. Obesity Research About Retatrutide

2. Type 2 Diabetes Research About Retatrutide

3. Liver Fat and NAFLD Models

Additional Research Areas Where Retatrutide May Benefit

Retatrutide Peptide Prices at Orion Peptides

Disclaimer

Referenced Citations

Research Use Only

Chemical Properties

Certificate of Analysis

Quality

HPLC Analysis

Mass Spectrometry (MS)

Third-Party Testing

Request COA

COA Lab Tests

Storage & Handling

Before Use (Uno⁠pened)

A‌fter Reconst‌itution (Liquid Form)

Storage During Travel‌

A‌fter Reconst‌itution (Liquid Form)

Related Compounds

Storage

Certificate of Analysis